ZyVersa Historical Balance Sheet
| ZVSA Stock | 1.13 0.01 0.88% |
Trend analysis of ZyVersa Therapeutics balance sheet accounts such as Total Assets of 39.2 M, Short Long Term Debt Total of 8.2 K, Other Current Liabilities of 1.9 M or Total Current Liabilities of 10.9 M provides information on ZyVersa Therapeutics' total assets, liabilities, and equity, which is the actual value of ZyVersa Therapeutics to its prevalent stockholders. By breaking down trends over time using ZyVersa Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining ZyVersa Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ZyVersa Therapeutics is a good buy for the upcoming year.
ZyVersa |
About ZyVersa Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of ZyVersa Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. ZyVersa Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ZyVersa Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ZyVersa currently owns. An asset can also be divided into two categories, current and non-current.
ZyVersa Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of ZyVersa Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ZyVersa Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on ZyVersa Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ZyVersa Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from ZyVersa Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ZyVersa Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.At present, ZyVersa Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 1.9 M, whereas Short and Long Term Debt Total is forecasted to decline to 8,223.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 9.2M | 108.8K | 8.7K | 8.2K | Total Assets | 1.1M | 118.5M | 22.1M | 39.2M |
ZyVersa Therapeutics balance sheet Correlations
Click cells to compare fundamentals
ZyVersa Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.